

Bringing data to life: a case-based discussion on LIBTAYO treatment in real clinical practice patients with advanced NSCLC*

For US Healthcare Professionals Only

Indications and Usage

LIBTAYO (cemiplimab-rwlc) in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation OR metastatic.

LIBTAYO as a single agent is indicated for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] $\geq 50\%$) as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation OR metastatic.

Important Safety Information

Warnings and Precautions

Severe and Fatal Immune-Mediated Adverse Reactions

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue at any time after starting treatment. While immune-mediated adverse reactions usually occur during treatment, they can also occur after discontinuation. Immune-mediated adverse reactions affecting more than one body system can occur simultaneously. Early identification and management are essential to ensuring safe use of PD-1/PD-L1-blocking antibodies. The definition of immune-mediated adverse reactions included the required use of systemic corticosteroids or other immunosuppressants and the absence of a clear alternate etiology. Monitor closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Please see additional Important Safety Information on following pages and click here for full [Prescribing Information](#).

REGISTER NOW


www.Medlive.com/v/aNSCLC
[FREE TO PARTICIPATE]

Program Description

Join us for a conversation with expert oncologists while they discuss how to evaluate patients that may be appropriate candidates for LIBTAYO and share firsthand stories about their experiences using LIBTAYO to treat patients with advanced NSCLC*.

*Advanced NSCLC (aNSCLC) is locally advanced NSCLC where patients are not candidates for surgical resection or definitive chemoradiation OR metastatic NSCLC

Featured Speakers - Sponsored by Regeneron



Dr. Misako Nagasaka M.D., Ph.D.

Medical Oncologist
Associate Professor
Division of Hematology/Oncology
Department of Medicine
UCI School of Medicine
Irvine, CA



Dr. Jyoti Malhotra M.D., M.P.H.

Medical Oncologist
Associate Professor
Director of Thoracic Medical Oncology
Department of Medical Oncology and Therapeutics Research
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, CA

This is a non-CME presentation and is not eligible for *AMA PRA Category 1 Credits*[™]

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, this Program is limited to U.S. Healthcare Professionals and persons with bona fide professional interest in the information presented. Attendance at this Program by guests or spouses is not permitted unless they would qualify as an appropriate attendee on their own. If a meal is provided, actively licensed Minnesota and Vermont prescribers may attend, but not partake in the meal. Full-time Federal Employees may attend and partake in the meal if the Program is considered widely attended (50 or more attendees). If not, they may attend, but not partake in the meal. Part-time Federal Employees acting in their civilian capacity may attend the Program and partake in the meal. Alcohol is not permitted in connection with Speaker Programs and will not be provided. The value of any meal provided in connection with the Program may be reported in accordance with federal and state laws and regulations. No CME credits offered for attendance of this program.